Revolution Medicines Inc (FRA:42Z)
€ 55 -1.5 (-2.65%) Market Cap: 9.33 Bil Enterprise Value: 7.95 Bil PE Ratio: 0 PB Ratio: 6.27 GF Score: 42/100

Revolution Medicines Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 12, 2022 / 11:00AM GMT
Release Date Price: €21.4 (-0.93%)
Robert Burns
HC Wainwright & Co LLC - Analyst

On to our next fireside chat. I'm Robert Burns, the Managing Director, and Senior Biotech Analyst at H.C. Wainwright. I am joined by Mark Goldsmith, the CEO of Revolution Medicines.

Thank you, Mark, for being here today.

Mark Goldsmith
Revolution Medicines Inc - President and CEO

Thanks, Robert. Really appreciate the opportunity.

Robert Burns
HC Wainwright & Co LLC - Analyst

No, of course. So why don't we just dive in. For those who may be unfamiliar with the Revolution Medicines' story? Can you provide a brief high-level overview of the company and your pipeline?

Mark Goldsmith
Revolution Medicines Inc - President and CEO

Sure. Happy to do so. Revolution Medicines is a biotech company focused entirely on RAS-addicted cancers. And that's a really important fundamental statement because by having the entire pipeline focused on the same a biologic area of focus, we developed great leverage in our know-how

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot